BridgeMD
Compares treatment options for Atrial Fibrillation
Official title Concomitant Hybrid Versus Catheter Ablation for Atrial Fibrillation With Hypertrophic Cardiomyopathy
ClinicalTrials.gov ID: NCT05610215
What this study is testing
- What it's testing
- The goal of this clinical trial is to compare the rhythm control effect in hypertrophic non-obstructive patients with non-paroxysmal atrial fibrillation by either concomitant catheter endocardial and thoracoscopic epicardial ablation or catheter ablation alone. The study aims to see if concomitant hybrid ablation can more effectively achieve rhythm control effect than catheter ablation alone in non-paroxysmal atrial fibrillation patients with hypertrophic cardiomyopathy.
A plain-language read of the study's public ClinicalTrials.gov listing. The study team confirms the details.
Who can take part
Ages 18 and older
You may be able to join if
- Patients' age is ≥18 y
- Clinically diagnosed hypertrophic cardiomyopathy (any left ventricular wall segment thickness ≥15 mm in genetical negative (or unknown genetical...
- Non-obstructed left ventricular outflow obstruction with peak gradients \<30mmHg
- Concomitant with persistent atrial fibrillation (7 days\<sustained episode lasting\<3 years) with drug-refractory symptoms.
- Be able to understand the contents of the trial, and provide written informed consent to participate in this investigation.
You likely can't join if
- Patients with left atrial size \>60 mm (2-dimensional echocardiography, parasternal long-axis view)
- Contraindicated to systemic anticoagulation
- Left ventricular ejection fraction ≤40%
- Concomitant with left atrium or left atrial appendage emboli
- Concomitant with a coronary or valvular disease that indicates intervention
- Ischaemic stroke within 2 months
See the full eligibility criteria
- Patients' age is ≥18 y
- Clinically diagnosed hypertrophic cardiomyopathy (any left ventricular wall segment thickness ≥15 mm in genetical negative (or unknown genetical status) patients or ≥13mm in genetical positive ones-as measured by any...
- Non-obstructed left ventricular outflow obstruction with peak gradients \<30mmHg
- Concomitant with persistent atrial fibrillation (7 days\<sustained episode lasting\<3 years) with drug-refractory symptoms.
- Be able to understand the contents of the trial, and provide written informed consent to participate in this investigation.
- Patients with left atrial size \>60 mm (2-dimensional echocardiography, parasternal long-axis view)
- Contraindicated to systemic anticoagulation
- Left ventricular ejection fraction ≤40%
- Concomitant with left atrium or left atrial appendage emboli
- Concomitant with a coronary or valvular disease that indicates intervention
- Ischaemic stroke within 2 months
- Previous ablation history
- Uncontrolled hyper/hypothyroidism
- End-staged kidney failure
- Concomitantly involved in other trials
- Pregnant or breastfeeding, or women of childbearing age not using a reliable contraceptive method
- Concomitant with bacteremia or at an active phase of infection
- Anatomically not suitable for thoracoscopic surgery(history of chest surgery or radiotherapy, etc.)
- Unwilling or unable to comply with all peri-ablation and follow-up requirements
The study team makes the final eligibility decision.
Where it's taking place
- Beijing, China
Compensation & support
Compensation mentioned.
ClinicalTrials.gov doesn't provide a reliable structured field for payment or travel support - confirm details with the study team.
Questions & answers
Do participants get paid in this trial?
This study's listing includes signals that participants may be compensated or receive a stipend. Amounts vary and are set by the study team - confirm the details with them.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 18 years and older. The study team makes the final eligibility decision.
Where is this trial taking place?
Study sites include Beijing, China. Enter your location above to see the nearest site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from ClinicalTrials.gov; the study team decides eligibility.